Moxifloxacin (Avelox)

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Also Known As:

Avelox; 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Actira; Avalox; BAY 12-8039; BAY 128039; BAY-12-8039; BAY-128039; Izilox; Moxifloxacin Hydrochloride; Octegra; Proflox; BAY 12 8039; BAY128039

Networked: 1813 relevant articles (254 outcomes, 380 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        Moxifloxacin: 1813

Experts

1.	Nuermberger, Eric L: 14 articles (01/2022 - 02/2004)
2.	Tyagi, Sandeep: 13 articles (01/2017 - 06/2002)
3.	Grosset, Jacques H: 13 articles (04/2015 - 02/2004)
4.	Arvis, P: 12 articles (02/2016 - 01/2001)
5.	Arvis, Pierre: 12 articles (01/2015 - 05/2003)
6.	Miravitlles, Marc: 12 articles (01/2015 - 01/2003)
7.	Lietman, Thomas M: 11 articles (01/2021 - 01/2012)
8.	Kowalski, Regis P: 11 articles (01/2019 - 09/2003)
9.	Romanowski, Eric G: 11 articles (01/2019 - 09/2003)
10.	Gumbo, Tawanda: 11 articles (11/2018 - 11/2004)

Related Diseases

1.	Infections 06/30/2014 - "Moxifloxacin administered for a mean of 10.0 days (range: 2.0 to 39.0 days) was highly effective: 96.7% of patients in the efficacy population (n=2152) improved and 93.2% were cured of infection during the study. " 03/01/2004 - "Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections." 03/01/2011 - "Clinical reports suggest that moxifloxacin may be effective for the treatment of odontogenic infections that can lead to serious complications. " 10/01/2005 - "How effective is moxifloxacin for the first-line treatment of patients with Helicobacter pylori infection?" 04/01/1998 - "These results suggested that BAY 12-8039 would be a promising agent for the eradication of respiratory tract pathogens and that clinical trials assessing its efficacy for the management of infections caused by these organisms are warranted."
2.	Endophthalmitis (Ophthalmia) 08/01/2021 - "Prophylactic IC moxifloxacin reduced the incidence of PCE with maximum benefit being observed for the subsidised patients and also helped achieve a significantly better visual acuity following the resolution of endophthalmitis." 08/01/2010 - "H2O2 exposure did not increase cellular toxicity Vigamox did not show significant toxicity on primary RPEs, TMCs, LECs, CECs, or human corneal endothelium at concentrations up to 150 microg/ml. The MIC90 of moxifloxacin for pathogens commonly encountered in endophthalmitis is known to be in the range of 0.25-2.5 microg/ml. Therefore, intracameral use of Vigamox at concentrations up to 150 microg/ml may be safe and effective for preventing endophthalmitis after intraocular surgery." 03/01/2008 - "No significant toxicity of moxifloxacin was seen on primary RPE cells, ARPE19 cells, or ONHA cells at concentrations up to 150 microg/mL. Intravitreal use of moxifloxacin up to this concentration may be safe and effective for the treatment of endophthalmitis." 09/01/2005 - "Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model." 08/01/2010 - "[Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? "
3.	Pneumonia (Pneumonitis) 05/15/2008 - "Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial." 01/01/2014 - "Moxifloxacin is effective and safe for treatment of community-acquired pneumonia with aspiration factors. " 05/01/2005 - "Our objective was to study to what extent MV could influence the efficacy of moxifloxacin in a rabbit model of pneumonia. " 07/01/2000 - "Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae." 07/01/2023 - "Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia."
4.	Tuberculosis (Tuberculoses) 11/01/2017 - "Further study is, however, needed to determine the safety of proposed higher doses and clinically validated targets for drug exposure to moxifloxacin associated with improved tuberculosis treatment outcomes. " 02/01/2021 - "Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials." 07/01/2017 - "Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis." 10/23/2015 - "WITHDRAWN: Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis." 02/01/2005 - "To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. "
5.	Cataract (Cataracts) 04/01/2018 - "The results suggest moxifloxacin is a safe option for intracameral use after cataract surgery." 04/01/2018 - "To study the safety parameters associated with intracameral moxifloxacin application five weeks after cataract surgery. " 09/01/2022 - "To evaluate corneal morphology after use of 0.5% intracameral moxifloxacin (ICM) in cataract surgery in patients who presented late with hard cataracts. " 09/01/2022 - "Impact on corneal morphology after cataract surgery with intracameral moxifloxacin in neglected hard cataracts." 02/17/2022 - "To describe a case of bilateral acute iris transillumination (BAIT)-like syndrome following intracameral moxifloxacin injection after cataract surgery. "

Related Drugs and Biologics

1.	Levofloxacin (Levaquin)
2.	Gatifloxacin (Zymar)
3.	Anti-Bacterial Agents (Antibiotics)
4.	Fluoroquinolones
5.	Ophthalmic Solutions (Eye Drops)
6.	Rifampin (Rifampicin)
7.	Ciprofloxacin (Cipro)
8.	Vancomycin
9.	Azithromycin (Zithromax)
10.	Quinolones

Related Therapies and Procedures

1.	Therapeutics
2.	Phacoemulsification
3.	Intravitreal Injections
4.	Topical Administration
5.	Duration of Therapy